CD3, T cell receptor complex (including CD3 γ/δ/ε/Zeta chains), is a core signaling molecule for T cell activation. CD20, a B cell surface antigen encoded by the MS4A1 gene, is the main target of monoclonal antibody therapies such as rituximab.
We conduct stability studies under different storage conditions and evaluate immune responses to ensure the effectiveness of bispecific antibodies when used in research.